Novakand Pharma AB (publ) (DB: 3EE0)
Health Care · Biotechnology · SE
€—
— today · — 1Y
Novakand Pharma AB (publ) (DB: 3EE0) operates in the Biotechnology industry within the Health Care sector.
trading between 0.00 and 0.16.
Tweenvest scores Novakand Pharma AB (publ) across four factors: quality 27/100. Its strongest factor is quality.
3EE0 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- €0.16
- 52-week low
- €0.00
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 5
- Next earnings
- —
About Novakand Pharma AB (publ)
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025. Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
- ISIN
- SE0015658570
- Founded
- 2010
- Listed since
- Sep 15, 2025
- Exchange
- Deutsche Boerse AG
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.